Kala raises $11.5 million in series A

Kala Pharmaceuticals Inc. (Waltham, Mass.) raised $11.5 million in a series A led by new investor Crown Venture Fund. Existing investors Lux Capital; Polaris Venture Partners; and Third Rock Ventures also participated. Kala's lead programs include preclinical topical treatments using its mucosal penetrating product technology to treat ocular inflammation and wet age-related macular degeneration (AMD) (see SciBX: Science-Business eXchange, July 12, 2012). ...